Fig. 5: MLN2238 treatment regulates expression of anti-apoptotic proteins Mcl-1 and Bcl-2, and Mcl-1 knockdown sensitizes HCC cells to MLN2238-mediated cell death. | Cell Death & Disease

Fig. 5: MLN2238 treatment regulates expression of anti-apoptotic proteins Mcl-1 and Bcl-2, and Mcl-1 knockdown sensitizes HCC cells to MLN2238-mediated cell death.

From: Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Fig. 5

Dose- a and time-dependent b effects of MLN2238 treatment on Mcl-1 and Bcl-2 expression determined by western blot analysis. a Cells exposed to the specified MLN2238 concentrations for 24 h. b Cells treated with 500 nM of MLN2238 for 24 and 48 h. c Left panels, Mcl-1 expression levels after 72 h of transfection with Mcl-1 siRNA (siMcl-1) in cells compared with cells transfected with control siRNA (siNC). Right panels, viability of cells transfected with Mcl-1 siRNA (siMcl-1) after treatment with the indicated MLN2238 concentrations for 24 h. d Representative western blotting of PARP and β-catenin levels expressed in Hep3B cells transfected with Mcl-1 siRNA (siMcl-1) or control siRNA (siNC) after 24 h of treatment with 500 nM of MLN2238. The 85 kDa form of PARP is indicated by an arrowhead. *P < 0.05 MLN2238 vs. control; #P < 0.005 MLN2238 vs. control

Back to article page